Your browser doesn't support javascript.
loading
Advancing drug discovery through assay development: a survey of tool compounds within the human solute carrier superfamily.
Digles, Daniela; Ingles-Prieto, Alvaro; Dvorak, Vojtech; Mocking, Tamara A M; Goldmann, Ulrich; Garofoli, Andrea; Homan, Evert J; Di Silvio, Alberto; Azzollini, Lucia; Sassone, Francesca; Fogazza, Mario; Bärenz, Felix; Pommereau, Antje; Zuschlag, Yasmin; Ooms, Jasper F; Tranberg-Jensen, Jeppe; Hansen, Jesper S; Stanka, Josefina; Sijben, Hubert J; Batoulis, Helena; Bender, Eckhard; Martini, Riccardo; IJzerman, Adriaan P; Sauer, David B; Heitman, Laura H; Manolova, Vania; Reinhardt, Juergen; Ehrmann, Alexander; Leippe, Philipp; Ecker, Gerhard F; Huber, Kilian V M; Licher, Thomas; Scarabottolo, Lia; Wiedmer, Tabea; Superti-Furga, Giulio.
Afiliação
  • Digles D; Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • Ingles-Prieto A; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Dvorak V; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Mocking TAM; Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
  • Goldmann U; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Garofoli A; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Homan EJ; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Di Silvio A; Axxam SpA, Bresso, Italy.
  • Azzollini L; Axxam SpA, Bresso, Italy.
  • Sassone F; Axxam SpA, Bresso, Italy.
  • Fogazza M; Axxam SpA, Bresso, Italy.
  • Bärenz F; Sanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
  • Pommereau A; Sanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
  • Zuschlag Y; Sanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
  • Ooms JF; Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
  • Tranberg-Jensen J; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Hansen JS; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Stanka J; Lead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
  • Sijben HJ; Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
  • Batoulis H; Lead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
  • Bender E; Lead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
  • Martini R; Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • IJzerman AP; Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
  • Sauer DB; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Heitman LH; Division of Drug Discovery and Safety, LACDR, Leiden University, Leiden, Netherlands.
  • Manolova V; CSL Vifor, StGallen, Switzerland.
  • Reinhardt J; Novartis Pharma AG, Basel, Switzerland.
  • Ehrmann A; Lead Identification and Characterization, Bayer Pharmaceuticals, Wuppertal, Germany.
  • Leippe P; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Ecker GF; Department of Pharmaceutical Sciences, University of Vienna, Vienna, Austria.
  • Huber KVM; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Licher T; Sanofi, Integrated Drug Discovery, Industriepark Hoechst, Frankfurt am Main, Hessen, Germany.
  • Scarabottolo L; Axxam SpA, Bresso, Italy.
  • Wiedmer T; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Superti-Furga G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Front Pharmacol ; 15: 1401599, 2024.
Article em En | MEDLINE | ID: mdl-39050757
ABSTRACT
With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https//re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article